
ACAD Stock Forecast & Price Target
ACAD Analyst Ratings
Bulls say
ACADIA Pharmaceuticals is a biopharmaceutical company with a promising pipeline, particularly in the areas of neurological and rare diseases. The success of pimavanserin and remlifanserin in treating psychosis associated with Parkinson's disease and Alzheimer's disease, respectively, as well as the potential approval of trofinetide for Rett syndrome, show potential for revenue growth. However, the company's stock is high risk due to potential drawbacks and competition in the market. Overall, ACADIA has the potential for long-term success, but investors should proceed with caution.
Bears say
ACADIA Pharmaceuticals is currently facing several challenges, such as underwhelming data from its pimavanserin drug in multiple indications, the need for further development and investment in a next-generation drug called remlifanserin, and the risk of competition and market pressure. Additionally, there is uncertainty surrounding the success of its ongoing clinical trials for Alzheimer's and Lewy Body Dementia psychosis. These factors, combined with the potential risks of safety concerns and regulatory hurdles, contribute to the financial analyst's negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Acadia Pharmaceuticals Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACAD Analyst Forecast & Price Prediction
Start investing in ACAD
Order type
Buy in
Order amount
Est. shares
0 shares